Last reviewed · How we verify
Tuberous sclerosis syndrome
Approved treatments
- Rapamune · Wyeth is now a wholly owned subsidiary of Pfizer
- Afinitor · Novartis
Afinitor works by blocking the mTOR protein, which is involved in cell growth and division. - Afinitor · Central European Society for Anticancer Drug Research
- Rapamune · Pfizer
Rapamune works by binding to the mTOR protein, inhibiting its activity and preventing the growth and proliferation of certain cells. - Rapamycin · Institut National de la Santé Et de la Recherche Médicale, France
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Tuberous sclerosis syndrome patent landscape — cliff calendar, originator estates, attackable patents
- Tuberous sclerosis syndrome treatment landscape brief
- Tuberous sclerosis syndrome treatment updates RSS
Frequently asked questions about Tuberous sclerosis syndrome
What drugs treat Tuberous sclerosis syndrome?
Tracked treatments include Rapamune, Afinitor, Rapamycin.
What is the treatment for Tuberous sclerosis syndrome?
Standard treatment for Tuberous sclerosis syndrome includes Rapamune, Afinitor, Rapamycin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Tuberous sclerosis syndrome patent cliff · Tuberous sclerosis syndrome CI report
- Treatment: Rapamune · Wyeth is now a wholly owned subsidiary of Pfizer
- Treatment: Afinitor · Novartis
- Treatment: Afinitor · Central European Society for Anticancer Drug Research
- Treatment: Rapamune · Pfizer
- Treatment: Rapamycin · Institut National de la Santé Et de la Recherche Médicale, France
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing